Multiple Myeloma Treatment Strategies with Novel Agents in 2011: A European Perspective
Article 2011 en
Authors
HL
Heinz Ludwig
MB
Meral Beksaç
JB
Joan Bladé
Abstract
1 min read
The arrival of the novel agents thalidomide, bortezomib, and lenalidomide has significantly changed our approach to the management of multiple myeloma and, importantly, patient outcomes have improved. These agents have been investigated intensively in different treatment settings, providing us with data to make evidence-based decisions regarding the optimal management of patients. This review is an update to a previous summary of European treatment practices that examines new data that have been published or presented at congresses up to the end of 2010 and assesses their impact on treatment practices.
Heinz Ludwig, Meral Beksaç, Joan Bladé, Mario Boccadoro, Jamie Cavenagh, Michèle Cavo, Meletios A Dimopoulos, Johannes Drach, Hermann Einsele, Thierry Façon, Hartmut Goldschmidt, Jean‐Luc Harousseau, U Hess, Nicolas Ketterer, Martin Kropff, Л. П. Менделеева, Gareth J. Morgan, Antonio Palumbo, Torben Plesner, Jesús F. San Miguel, Ofer Shpilberg, Pia Sondergeld, Pieter Sonneveld, Sonja Zweegman
Heinz Ludwig, Hervé Avet‐Loiseau, Joan Bladé, Mario Boccadoro, Jamie Cavenagh, Michèle Cavo, Faith E. Davies, Javier de la Rubia, Sosana Delimpasi, Meletios A Dimopoulos, Johannes Drach, Hermann Einsele, Thierry Façon, Hartmut Goldschmidt, U Hess, Ulf-Henrik Mellqvist, Philippe Moreau, Jesús F. San Miguel, Pia Sondergeld, Pieter Sonneveld, Miklós Udvardy, Antonio Palumbo
Discussion(0)
No comments yet. Be the first to comment.